[ad_1]
“I think 90% of pharmaceutical spend in the UK, and I’m pretty sure it’s similar in the US, is for generics… so, you [the original inventor] may well retain market share, but the price will fall,” says Graham Cookson chief executive of the Office of Health Economics, the world’s oldest health economics research organisation.
[ad_2]
Source link